Dragon Pharma SLU-PP-332 500 mcg is a cutting-edge research compound belonging to the exercise mimetic class. SLU-PP-332 functions as a potent agonist of the estrogen-related receptor alpha (ERRα), a key transcriptional regulator of metabolic pathways including fatty acid oxidation, mitochondrial biogenesis, and glucose utilization. This mechanism allows researchers to study exercise-like metabolic adaptations in laboratory models without physical activity interventions. The 500 mcg oral tablet formulation provides consistent dosing for in vivo research protocols.
If your laboratory requires reliable Dragon Pharma SLU-PP-332 for metabolic studies, this 100-tablet sachet delivers 50 mg total compound. For researchers investigating exercise mimetics and metabolic reprogramming, finding legit SLU-PP-332 from a verified source ensures reproducible data. This compound has shown promise in research models for increasing energy expenditure and improving metabolic parameters.
Metabolic flexibility and fat oxidation are central to body composition research. SLU-PP-332 research explores its effects on fatty acid metabolism, endurance capacity, and mitochondrial function. The compound's ability to activate ERRα pathways makes it relevant for studies on exercise-independent metabolic improvements. For researchers examining alternative approaches to metabolic health or performance enhancement mechanisms, SLU-PP-332 represents a novel research tool.
Important: This product is for laboratory research purposes only. Not for human or veterinary use. Lab test report for this batch is available below – third-party verified by Analiza Bialek.
Note for researchers: SLU-PP-332 is an emerging compound in metabolic research. For best results, follow established research protocols and always source legit SLU-PP-332 from Dragon Pharma.
For laboratory research use only. SLU-PP-332 is a potent ERR agonist for research purposes. Proper dosing accuracy and adherence to IACUC protocols are essential. Not for human or veterinary use.
Based on available research literature, typical SLU-PP-332 dosing in rodent models falls within this range:
For research involving precise oral administration of SLU-PP-332 500 mcg tablets:
SLU-PP-332 is gaining attention in metabolic research for its unique ERRα agonist mechanism, distinct from traditional thermogenic compounds. Its oral bioavailability makes it suitable for chronic administration studies without injection stress.
Popular research stacks and comparisons include:
Research Note: Individual responses vary in animal models. Maintain detailed research logs and adjust protocols based on specific study endpoints. Always follow institutional and laboratory safety guidelines.
At Dragon Pharma, every batch of research compounds undergoes independent third-party HPLC testing to verify dosage, purity, and identity. Below are the latest test results for Dragon Pharma SLU-PP-332 500 mcg, analyzed by Analiza Bialek.
With the proliferation of unverified research chemicals, independent lab analysis is the only method to confirm compound identity and potency. Legit SLU-PP-332 should meet strict dosage specifications. Dragon Pharma commits to full transparency — batch-specific COAs are published for all compounds.
For more information on SLU-PP-332 and ERRα research, refer to this PubMed study on ERRα agonists.
🔬 Every batch verified. All Dragon Pharma research compounds undergo third-party HPLC testing. The certificate for each batch is published here.
All Dragon Pharma SLU-PP-332 500 mcg orders ship directly from authorized distribution points. Outer packaging is discreet with no mention of product contents — just a plain box with a shipping label. Your privacy and research confidentiality are priorities.
Counterfeit research compounds are a genuine concern. Here's how to confirm you're receiving authentic Dragon Pharma SLU-PP-332:
⚠️ Important: Only purchase from authorized sources. If a deal seems too good to be true, it probably is. Fake products may contain incorrect compounds or harmful impurities. Always verify before using in research.
For complete delivery details, tracking policy, international customs, and reshipment terms, please see our Shipping Info page.
Dragon Pharma SLU-PP-332 500 mcg tablets require proper storage to maintain compound integrity for research validity.
Before using SLU-PP-332 tablets in your research, always inspect the product:
⚠️ Research note: Degraded compounds can produce unreliable research data. If you suspect your SLU-PP-332 has been stored improperly, do not use it in critical research. Contact support for batch verification.
Keep out of reach of children and unauthorized personnel. Follow institutional laboratory safety guidelines for handling research compounds.
SLU-PP-332 is a novel exercise mimetic compound that activates ERRα (estrogen-related receptor alpha), a key transcriptional regulator of metabolic genes. It promotes fatty acid oxidation, mitochondrial biogenesis, and glucose utilization in research models.
Yes. Dragon Pharma SLU-PP-332 is manufactured under strict quality standards with batch traceability, QR code verification, and third-party lab testing from Analiza Bialek. The current batch tested at 534.91 mcg (106.98% of label claim). To ensure you receive legit SLU-PP-332, always verify the scratch-off code.
SLU-PP-332 is formulated as oral tablets for research administration. Tablets can be administered whole, split into fractions, or crushed and suspended for gavage studies. Oral administration provides consistent systemic exposure.
Based on available literature, typical dosing in rodent models ranges from 0.1-1 mg per kg body weight. Using Dragon Pharma 500 mcg tablets, doses of 250-500 mcg can be achieved. Calculate based on research subject weight.
SLU-PP-332 activates ERRα receptors, while GW501516 targets PPARδ. Both pathways influence fat oxidation and endurance, but through different transcriptional mechanisms. Some researchers combine them for dual pathway studies.
Many research protocols involve stacking SLU-PP-332 with other metabolic compounds. Common stacks include GW501516 for ERRα/PPARδ dual pathway research or AICAR for AMPK interaction studies. Always follow proper research protocols.
Store at controlled room temperature (15–25°C / 59–77°F) in the original sachet with desiccant. Keep away from moisture, humidity, and direct light. After opening, reseal tightly.
Each Dragon Pharma SLU-PP-332 sachet contains 100 tablets at 500 mcg each (50 mg total). At a typical research dose of 500 mcg daily, one sachet provides 100 research days. Most metabolic studies require 1-2 sachets depending on protocol length.
Neither. SLU-PP-332 is a research compound for laboratory use only. It is not approved by the FDA for human or veterinary use. Dragon Pharma sells this product strictly for research purposes.
You're in the right place. Dragon Pharma SLU-PP-332 500 mcg is available for research purposes with USA domestic and international shipping. Every batch is third-party tested by Analiza Bialek with results published above. Avoid third-party resellers — purchase directly from authorized Dragon Pharma distributors to ensure you receive legit SLU-PP-332.
Still have questions? Contact our support team for research-related inquiries. For specific medical or clinical advice, consult with qualified professionals.
Please log in to write SLU-PP-332 500 mcg review.